{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:50:14Z","timestamp":1791280214432,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Talquetamab (TAL) frequently induces a distinctive dysgeusia that diminishes eating enjoyment, oral intake, and quality of life in patients with multiple myeloma (MM). Patient-centered, evidence-based nutritional guidance tailored to TAL-related sensory phenotypes is scarce. This mixed-methods study aimed to characterize patient experiences, identify preferred dietary adaptations, and translate these findings into a proposed exploratory clinical workflow and a digital companion support concept for future validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, single-center exploratory mixed-methods study was conducted in talquetamab-treated patients with multiple myeloma who reported new-onset taste change (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925). Patient-reported dysgeusia, xerostomia symptoms, dietary experiences, and coping strategies were captured using a structured questionnaire with free-text fields. Taste change and xerostomia were assessed by patient report; objective psychophysical taste testing and sialometry were not performed in this cohort. Free-text responses were analyzed by two independent coders using reflexive thematic analysis with iterative consensus. Quantitative data were summarized descriptively. Integrated findings were translated in interprofessional focus groups into two exploratory supportive-care outputs: a proposed clinical workflow and a digital companion blueprint for future validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients described heterogeneous and individualized taste disturbances, including reduced or unpleasant perception of sweet flavors, bitter\/sour aversions, spice-related mucosal sensitivity, and reduced enjoyment of meals. Patient-reported xerostomia symptoms aggravated intolerance to dry or fibrous foods and impaired swallowing comfort. Frequently reported coping strategies included mild herbs and aroma cues, umami-rich additions, sauce- or soup-based texture modification, temperature and plating adjustments, saliva-supportive measures, and environmental or behavioral strategies. Based on these findings, we developed an exploratory supportive-care workflow incorporating cycle-based symptom screening, prospective use of validated taste assessment where feasible, structured xerostomia and nutritional-risk assessment, phenotype-oriented dietary suggestions, safety escalation, and follow-up. A digital companion blueprint (GUSTABOR) was conceptualized to support future individualized dietary guidance after usability and effectiveness testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Talquetamab-related dysgeusia is clinically meaningful, heterogeneous, and closely linked to oral dryness symptoms, food texture tolerance, eating enjoyment, and social participation. The proposed workflow and digital companion blueprint should be interpreted as exploratory supportive-care concepts derived from patient-reported experience, not as validated clinical tools. Prospective multicenter studies using validated taste instruments, objective salivary-flow assessment, nutritional endpoints, and implementation outcomes are required before routine clinical adoption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for cancer survivors<\/jats:title>\n                    <jats:p>Structured symptom screening, validated taste assessment where feasible, and individualized nutrition support may help identify patients at risk for reduced intake, weight loss, and impaired quality of life during talquetamab therapy. Digital support could broaden access to tailored guidance, but should be implemented only after prospective evaluation of usability, safety, resource requirements, and clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10863-z","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:18:11Z","timestamp":1781680691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept"],"prefix":"10.1007","volume":"34","author":[{"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Panther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Kadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6tz","family":"Gelbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"24","key":"10863_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244","journal-title":"N Engl J Med"},{"issue":"4","key":"10863_CR2","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A et al (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol 12(4):e269\u2013e281","journal-title":"Lancet Haematol"},{"issue":"4","key":"10863_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/10600280241271192","volume":"59","author":"J Shaver","year":"2025","unstructured":"Shaver J, Horton D, Halford Z (2025) Targeting GPRC5D with talquetamab: a new frontier in bispecific antibody therapy for relapsed\/refractory multiple myeloma. Ann Pharmacother 59(4):350\u2013363","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10863_CR4","first-page":"20","volume":"32","author":"A Laheij","year":"2023","unstructured":"Laheij A, van de Donk N (2023) Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer 32(1):20","journal-title":"Support Care Cancer"},{"issue":"10","key":"10863_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A et al (2024) Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk 24(10):665-693.e14","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10863_CR6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2025.16.7.15","author":"T Sandahl","year":"2025","unstructured":"Sandahl T, Sandahl PD et al (2025) Management of patients with relapsed\/refractory multiple myeloma treated with talquetamab: highlights from pharmacists\u2019 perspectives. J Adv Pract Oncol. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.15","journal-title":"J Adv Pract Oncol"},{"issue":"23","key":"10863_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71401","volume":"14","author":"A Fleischer","year":"2025","unstructured":"Fleischer A et al (2025) Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan. Cancer Med 14(23):e71401","journal-title":"Cancer Med"},{"issue":"4","key":"10863_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jha2.971","volume":"5","author":"S Naqvi","year":"2024","unstructured":"Naqvi S et al (2024) Weight loss and dysgeusia in relapsed\/refractory multiple myeloma patients treated with talquetamab. EJHaem 5(4):789\u2013792","journal-title":"EJHaem"},{"issue":"14","key":"10863_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35927","volume":"131","author":"C Schinke","year":"2025","unstructured":"Schinke C et al (2025) Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study. Cancer 131(14):e35927","journal-title":"Cancer"},{"issue":"5","key":"10863_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2024.151712","volume":"40","author":"D Catamero","year":"2024","unstructured":"Catamero D et al (2024) Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Semin Oncol Nurs 40(5):151712","journal-title":"Semin Oncol Nurs"},{"issue":"1","key":"10863_CR11","first-page":"2","volume":"41","author":"C Mueller","year":"2003","unstructured":"Mueller C et al (2003) Quantitative assessment of gustatory function in a clinical context using impregnated \u201ctaste strips.\u201d Rhinology 41(1):2\u20136","journal-title":"Rhinology"},{"issue":"2","key":"10863_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00415-009-0088-y","volume":"256","author":"BN Landis","year":"2009","unstructured":"Landis BN et al (2009) \u201cTaste Strips\u201d - a rapid, lateralized, gustatory bedside identification test based on impregnated filter papers. J Neurol 256(2):242\u2013248","journal-title":"J Neurol"},{"issue":"2","key":"10863_CR13","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1188\/13.ONF.E79-E85","volume":"40","author":"T Kano","year":"2013","unstructured":"Kano T (2013) Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum 40(2):E79\u2013E85","journal-title":"Oncol Nurs Forum"},{"issue":"12","key":"10863_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/annonc\/mdw422","volume":"27","author":"V Hagelstein","year":"2016","unstructured":"Hagelstein V et al (2016) Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u2122). Ann Oncol 27(12):2294\u20132299","journal-title":"Ann Oncol"},{"issue":"9","key":"10863_CR15","first-page":"3915","volume":"24","author":"MJ Hjermstad","year":"2016","unstructured":"Hjermstad MJ et al (2016) International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15. Support Care Cancer 24(9):3915\u20133924","journal-title":"Support Care Cancer"},{"issue":"25","key":"10863_CR16","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.21.01208","volume":"39","author":"V Mercadante","year":"2021","unstructured":"Mercadante V et al (2021) Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline. J Clin Oncol 39(25):2825\u20132843","journal-title":"J Clin Oncol"},{"issue":"8","key":"10863_CR17","first-page":"551","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C et al (2024) MASCC\/ISOO Clinical Practice Statement: clinical assessment of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer 32(8):551","journal-title":"Support Care Cancer"},{"key":"10863_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CMAR.S441550","volume":"17","author":"KC Miller","year":"2025","unstructured":"Miller KC, Hamadeh I, Tan CR (2025) Perspectives on talquetamab and its utility in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res 17:743\u2013756","journal-title":"Cancer Manag Res"},{"issue":"13","key":"10863_CR19","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD (2016) Sample size in qualitative interview studies: guided by information power. Qual Health Res 26(13):1753\u20131760","journal-title":"Qual Health Res"},{"key":"10863_CR20","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/COPD.S473790","volume":"19","author":"LM Huang","year":"2024","unstructured":"Huang LM et al (2024) A qualitative study on illness perception and coping behaviors among patients with chronic obstructive pulmonary disease: implications for intervention. Int J Chron Obstruct Pulmon Dis 19:2467\u20132479","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10863_CR21","doi-asserted-by":"publisher","first-page":"2507443","DOI":"10.1080\/22423982.2025.2507443","volume":"84","author":"E Breivik","year":"2025","unstructured":"Breivik E, Ervik B, Kitzm\u00fcller G (2025) Preparing for home death in rural areas - the experience of family caregivers providing palliative cancer care. Int J Circumpolar Health 84(1):2507443. https:\/\/doi.org\/10.1080\/22423982.2025.2507443","journal-title":"Int J Circumpolar Health"},{"issue":"3","key":"10863_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738","volume":"131","author":"JM Sands","year":"2025","unstructured":"Sands JM et al (2025) Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3\u2013targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer 131(3):e35738","journal-title":"Cancer"},{"issue":"8","key":"10863_CR23","first-page":"548","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C et al (2024) MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer 32(8):548","journal-title":"Support Care Cancer"},{"issue":"5","key":"10863_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/13543784.2025.2511179","volume":"34","author":"D Pan","year":"2025","unstructured":"Pan D et al (2025) Emerging GPRC5D-targeted therapies for multiple myeloma: a comprehensive review. Expert Opin Investig Drugs 34(5):379\u2013389","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10863_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P et al (2024) GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J 14(1):24","journal-title":"Blood Cancer J"},{"issue":"6","key":"10863_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"issue":"4","key":"10863_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","volume":"31","author":"E Basch","year":"2025","unstructured":"Basch E et al (2025) Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. Nat Med 31(4):1225\u20131232","journal-title":"Nat Med"},{"key":"10863_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2021.01.021","volume":"157","author":"L Gunn","year":"2021","unstructured":"Gunn L et al (2021) Taste dysfunction following radiotherapy to the head and neck: a systematic review. Radiother Oncol 157:130\u2013140","journal-title":"Radiother Oncol"},{"issue":"4","key":"10863_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2018.06.016","volume":"56","author":"A van der Werf","year":"2018","unstructured":"van der Werf A et al (2018) Taste alterations during treatment with protein kinase inhibitors: a pilot study. J Pain Symptom Manage 56(4):e1\u2013e4","journal-title":"J Pain Symptom Manage"},{"issue":"21","key":"10863_CR30","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1002\/cncr.34444","volume":"128","author":"M Scordo","year":"2022","unstructured":"Scordo M et al (2022) A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation. Cancer 128(21):3850\u20133859","journal-title":"Cancer"},{"issue":"1","key":"10863_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","volume":"15","author":"S Al Hadidi","year":"2025","unstructured":"Al Hadidi S et al (2025) Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 15(1):196 https:\/\/doi.org\/10.1038\/s41408-025-01386-7","journal-title":"Blood Cancer J"},{"issue":"4","key":"10863_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH et al (2025) A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. Hemasphere 9(4):e70114","journal-title":"Hemasphere"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10863-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:02Z","timestamp":1784052182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10863-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10863"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10863-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the University of W\u00fcrzburg (AZ 119\/22) and conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for study participation and publication of anonymized data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All included patients gave their consent for publication of the collected data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AF received honoraria from GSK, BMS and Janssen. JW: Consultancy for Johnson&Johnson, Sanofi, Take\u00acda, Pfizer, Oncopeptides, Skyline Dx; Honoraria from GSK, Johnson&Johnson, Pfizer and Beigene; Research support from BMS.  LR received honoraria from Amgen, BMS, GSK, Janssen, Sanofi, and Pfizer and research funding from BMS. The remaining authors declare no conflicts of interest. KMK received Honoraria from Abbvie, Beigene, BMS, GSK, Johnson&Johnson, Menarini, Novartis, Pfizer and Sanofi. CS: consultancy for Acus Health, Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer; honoraria from Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Takeda, Sanofi; other (travel expenses\/congress support): Acus Health, Astra Zeneca, BeOne, Janssen-Cilag, Menarini Stemline, oncopeptides, Sanofi. AG served as consultant and\/or has received honoraria or travel costs from Allmiral, Amgen, Bristol-Myers Squibb, Immunocore, MSD Sharp & Dohme; Novartis, Pierre Fabre Pharmaceuticals, Pfizer, Regeneron, Roche and Sanofi Genzyme, outside the submitted work.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"668"}}